123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 2, 2017, Pages 234-241

  Lewington, V ^a   Lambert, B ^b   Poetschger, U ^c   Sever, Z Bar ^d   Giammarile, F ^e   McEwan, A J B ^f   Castellani, Rita ^g   Lynch, T ^h   Shulkin, B ⁱ   Drobics, M ^j   Staudenherz, A ^k   Ladenstein, R ^c,l  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GHENT UNIVERSITY   (Belgium)

^c CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^d SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f CROSS CANCER INSTITUTE   (Canada)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h Northern Ireland Cancer Centre   (United Kingdom)

ⁱ St Jude Children's Research Hospital   (United States)

^j AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^k UNIVERSITY OF VIENNA   (Austria)

^l ST ANNA CHILDREN S HOSPITAL   (Austria)

more..

Author keywords

123 meta iodobenzylguanidine 123I mIBG ; Imaging; Neuroblastoma; Scintigraphy; SIOPEN R NET; Skeleton

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANTINEOPLASTIC AGENT; (3 IODOBENZYL)GUANIDINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; ASSESSMENT OF HUMANS; BONE; BONE DISEASE; BONE METASTASIS; BRAIN SCINTISCANNING; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC TEST ACCURACY STUDY; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; INDUCTION CHEMOTHERAPY; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; NEUROBLASTOMA; QUANTITATIVE DIAGNOSIS; RATING SCALE; REPRODUCIBILITY; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SIOPEN; TREATMENT RESPONSE; BONE TUMOR; CLASSIFICATION; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; EUROPE; INTERNATIONAL COOPERATION; MULTICENTER STUDY; OBSERVER VARIATION; PRACTICE GUIDELINE; PROCEDURES; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; STANDARDS;

3-IODOBENZYLGUANIDINE; BONE NEOPLASMS; EUROPE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INTERNATIONALITY; NEUROBLASTOMA; OBSERVER VARIATION; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84988715304     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-016-3516-0     Document Type: Article

References (14)

1. Vik TA, Pfluger T, Kadota R, et al. I-123 mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784–90.
2. Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:388–402.
3. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21:2486–91.
4. Katzenstein HM, Cohn SL, Shore RM, et al. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol. 2004;22:3909–15.
5. Ady N, Zucker JM, Asselain B, et al. A new 123I-MIBG whole body scan scoring method. Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer. 1995;31A:256–61.
6. Frappaz D, Bonneu A, Chauvot P, et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol. 2000;34:237–41.
7. Huang S-C. Anatomy of SUV. Nucl Med Biol. 2000;27:643–6.
8. Sugawara Y, Zasadny KR, Neuhofff AW, et al. Re-evaluation of the standardised uptake value for FDG: variations with body weight and methods for correction. Radiology. 1999;213:521–5.
9. Olivier P, Colharina P, Fettich J, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003;30:B45–50.
10. Pearson AD, Pinkerton CR, Lewis IJ, et al. High dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomized trial. Lancet Oncol. 2008;9:247–56.
11. Bland JM, Altman DG. Statistical Methods for assessing agreement between two methods of clinical measurements. Lancet. 1986;1:307–10.
12. Shrout PE, Fleiss JL. Intraclass correlations: Uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.
13. Matthay K, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102:1319–26.
14. Taggart DR, Han MM, Quach A, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and 18F fluroodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27:5343–9.